Table 2.
Summarized characteristics of trials included in indirect comparisons for assessment of transitivity*.
| Potential effect modifiers | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|---|---|---|---|---|
| Age (years)a | 55 (55–56) | 58.5 (56–71) | 60 (56–67) | 60 (56–64) |
| Percentage of female patientsa | 39% (39–42%) | 43% (35–53%) | 43% (35–52%) | 45% (43–47%) |
| Percentage of patients with renal dysfunctiona | 5.0%c | 8.8% (6.9–21.5%) | 6.5% (5.0–9.3%) | 6.9% (6.5–7.3%) |
| Percentage of patients with cancera,b | 4.2% (3.9–5.0%) | 7.7% (4.7–12.0%) | 7.0% (2.5–9.6%) | 9.2%c |
| Treatment administration | 150 mg twice daily | 15, 20, 30, or 40 mg twice daily; or 10 mg once daily | 2.5, 5, or 10 mg twice daily; or 20 mg once daily | 30 or 60 mg once daily |
| Treatment duration (months)a | 6c | 6 (1–12) | 3 (1–8) | 7.5 (3–12) |
| Definition and assessment of VTE/MB | Consistent between all the trials | |||
| Follow-up period (months)a | 6 (6–36) | 7.5 (3–24) | 6 (3–8) | 12 (12–12) |
| Time in therapeutic range when control groups as VKA or LMWH+VKAa | 60.0% (56.9–65.3%) | 60.2% (57.7–62.7%) | 70.1%c | 63.5%c |
*
Unless specified, data only shown for the intervention groups assuming clinical equipoise between DOAC groups and non-DOAC groups.
a
Data shown as median (range);
b
Data excluding trials that had patients with cancer exclusively;
c
Data only shown for a single trial.